
    
      This study is a single-center, non-randomized, open label, no control, prospective clinical
      trial to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT
      cells from of a blood-related donor of Hepatocellular Carcinoma (HCC) Patients. This study
      will include the following sequential phases: sign informed consent, γδT cell pre-culture,
      screening and registration to the trial, apheresis, γδT cell preparation, treatments and
      follow-ups.
    
  